Phase 3 Study Of Early Versus Standard Zoledronic Acid To Prevent Skeletal Related Events

Principal Investigator: Nancy Dawson, Oncology
Disease Stage: Advanced

A randomized double-blind, placebo-controlled phase 3 study of early versus standard zoledronic acid to prevent skeletal related events in men with prostate cancer metastatic to bone.

This study is for men with prostate cancer that has spread to the bone who have not yet been treated with hormones. It is known from previous studies that treatment with zoledronic acid decreases the risk of bone related events, such as fractures,in men with prostate cancer that has spread to the bones and continues to grow with hormone treatment. This study is being done to find out whether it is better to start zoledronic acid at the same time as hormone treatment instead of afterwards.

Contact the Lombardi CancerLine to learn more. Phone: 202-444-4000